Insulet's Closed-Loop System Shows 24% Time-in-Range Boost for Type 2 Diabetes — Insulet Corporation

Event summary

Insulet's EVOLUTION 2 study showed a 24% improvement in time-in-range (TIR) for type 2 diabetes patients using its fully closed-loop (FCL) automated insulin delivery system.
The study included 24 diverse participants, with TIR increasing to 68% and time below range (TBR) remaining under 0.14% with no severe hypoglycemia or DKA events.
Over 90% of participants chose to continue into the ongoing extension phase, indicating strong interest in the FCL system.
Insulet plans to start its pivotal EVOLVE study in 2026, aiming for a 510(k) filing in 2027 and commercial launch in 2028.

The big picture

Insulet's study results position it at the forefront of a shift toward fully automated insulin delivery for type 2 diabetes, a market where only a quarter of insulin users achieve optimal HbA1c levels. The company's tubeless Omnipod platform offers a competitive edge in user experience, but success will depend on regulatory approval and adoption rates among a historically underserved patient population.

What we're watching

Regulatory Pathway: Whether Insulet can successfully navigate the FDA's 510(k) process for its FCL system, given the stringent requirements for automated insulin delivery devices.
Market Adoption: The pace at which type 2 diabetes patients and healthcare providers will embrace fully automated insulin delivery systems, particularly given the current reliance on manual insulin management.
Competitive Dynamics: How Insulet's progress compares to competitors like Tandem Diabetes Care and Medtronic, both of which are also developing advanced closed-loop systems.